Inactivated Vaccine Market Expected to Grow Faster According to New Research Report

0

Inactivated Vaccine Market is expected to have a highly positive outlook for the next five years 2018–2026 according to a recently released Inactivated Vaccine Market research report. The report has been added in his large database by Coherent Market Insights.

Introduction of new inactivated vaccines after completion of clinical studies are expected to boost growth of the inactivated vaccines market over the forecast period. For instance, in 2017, Merck’s investigational inactivated varicella zoster virus vaccine (V212) showed a decrease in the incidence of herpes zoster case by an estimated 64% in immunocompromised subjects in the first phase 3 trial. Clinical studies also revealed that V212 lessens the incidence of herpes zoster pain by around 69.5%. Moreover, V212 demonstrated 83.7% reduction in the incidence of post herpetic neuralgia.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1905

Rising prevalence of various viral and bacterial diseases around the globe have increased the demand for inactivated vaccines, which in turn will fuel the market growth. For instance, according to the World Health Organization (WHO) report in 2018, annual epidemics due to influenza were estimated to result in around 3 to 5 million cases of severe illness and around 290,000 to 650,000 deaths. Moreover, WHO 2018 report also showed that around 21 million cases and 222,000 typhoid-related deaths occur annually worldwide.

Department of Health and Human Services shifted fund of around US$ 81 million from other projects, to continue the work on developing vaccines to fight Zika virus. Asia Pacific is expected to witness growth in the market, followed by Europe, owing to growing activities in the healthcare research and development of new innovative products. For instance, in 2013, Bharat Biotech launched JENVAC vaccine to provide long-term protection and immunogenicity against Japanese encephalitis. The important benefit of this novel fully indigenous inactivated vaccine is that it can be administered during disease epidemics, as it is an inactivated vaccine and is highly purified.

Major players operating in the global inactivated vaccine market include;

* GlaxoSmithKline Plc.

* Seqirus.

* Valneva SE.

* Pfizer Inc.

* Merck & Co., Inc.

* Emergent BioSolutions.

* Bharat Biotech.

* Sanofi.

Major market players are involved in adopting market strategies such as mergers, acquisitions, partnership, collaborations, and development of new products with leading companies and research institutes, in order to retain dominant position in the market. For instance, in 2017, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline Plc’s Shingrix, a zoster vaccine recombinant for the prevention of shingles in adults above the age of 50 years. Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses.

Request For Customization Of This Business Research Report: https://www.coherentmarketinsights.com/insight/request-customization/1905

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Share.

About Author

Adam Nurse was born and raised in Buffalo. He has written for the Huffington Post, MSNBC and Passport Magazine. In regards to academics, Adam earned his BBA from St. John's University. Adam covers entertainment and culture stories here at Oak Tribune.